Premium
Upstream Bio Inc (UPB)
NASDAQ
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. We are developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphop... Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. We are developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin ("TSLP"), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Preclinical and clinical data to date demonstrate verekitug's highly potent inhibition of the TSLP receptor, which we believe will translate to a differentiated product profile, including improved clinical outcomes, substantially extended dosing intervals and the potential to treat a broad spectrum of patients. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.46 | 5.80075662043 | 7.93 | 9.29 | 6.67 | 268989 | 8.36814318 | CS |
| 4 | 0.41 | 5.13784461153 | 7.98 | 9.29 | 6.65 | 236193 | 7.89002914 | CS |
| 12 | -11.965 | -58.7816261361 | 20.355 | 20.94 | 6.65 | 336276 | 12.74724872 | CS |
| 26 | -13.11 | -60.976744186 | 21.5 | 29.35 | 6.65 | 321922 | 17.30788897 | CS |
| 52 | -13.11 | -60.976744186 | 21.5 | 29.35 | 6.65 | 321922 | 17.30788897 | CS |
| 156 | -13.11 | -60.976744186 | 21.5 | 29.35 | 6.65 | 321922 | 17.30788897 | CS |
| 260 | -13.11 | -60.976744186 | 21.5 | 29.35 | 6.65 | 321922 | 17.30788897 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
